News

Jacques Grosset Interview

Dr. Jacques Grosset
Dr. Jacques Grosset

Dr. Jacques Grosset’s biography is excerpted from his staff page on the Johns Hopkins Medicine website.

Since the beginning of my professional life I have been involved in research to improve the control of tuberculosis, mainly by improving treatment of tuberculosis and preventing the development of drug resistance.

Tuberculosis was a leading cause of death in industrialized countries when I started my medical studies.

During the past 45 years, I have participated in the development of nearly all new drug regimens used for tuberculosis and a number of other mycobacterial diseases, namely leprosy, M. avium complex infection in HIV-infected persons, and M. ulcerans infection (Buruli ulcer). Using the murine experimental model, I directed the development of an antibiotic regimen that led to the first clinical that demonstrated the efficacy of this treatment for Buruli ulcer. I also participated in the design and evaluation of this trial. At present, my primary involvement is in the use of the mouse model to investigate the efficacy of new drugs and new drug combinations in human diseases caused by mycobacteria for improving both the efficacy of treatment and the implementation of Directly Observed Therapy (DOT).

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...